Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

NCT04874129 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: YYC506-T and YYC506-A (phase 1)
DRUG: YYC506 (phase 1)
DRUG: YYC506-T and YYC506-A (phase 2)
DRUG: YYC506 (phase 2)

Sponsor

Yooyoung Pharmaceutical Co., Ltd.